News
2h
Barchart on MSNIs Gilead Sciences Stock Outperforming the S&P 500?With a market cap of around $136 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. The Foster City, ...
We’re proud to share that “The Adventure Jar,” a children’s book supporting families impacted by metastatic breast cancer (MBC), has received two 2025 Bronze Anvil Awards from the Public Relations ...
7h
Barchart on MSNGilead Short Strangle Could Net $395 In Short OrderGilead Sciences (GILD) is currently showing above average volatility with an IV Percentile of 95% and an IV Rank of 70.73%.
The shift toward universal screening for diseases like hepatitis C, hepatitis B, and HIV removes part of the burden of ...
J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...
On Monday, analysts at Morgan Stanley reiterated their Overweight rating on Gilead Sciences, Inc. (NASDAQ:GILD), while ...
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results